Precision Biotech Taiwan Corp. & HealthNet MEA Explore the UAE Roll-out of Botanical EX
Published: 11 Jun 2026
Author: Towards Healthcare
Announcement of the UAE launch of Botanical EX by HealthNet MEA & Precision Biotech Taiwan Corp, an advanced exosome-based aesthetic and skin wellness platform evolved to assist emerging needs of modern regenerative aesthetics & professional skincare practice.
The Botanical EX range comprises Skin, Hair, and Anti-Aging Face Mask, which has been unveiled by Precision Biotech Taiwan Corp., a multi-award-winning biotechnology leader that specialises in exosome science, immune cell preparation technologies, cell therapy, & gene therapy novelty.
According to Towards Healthcare, the Middle East & Africa bioregenerative aesthetic injectables market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 218.89 million in 2026 to approximately USD 746.24 billion by 2035, representing a compound annual growth rate (CAGR) of 14.6% from 2026 to 2035. Respective expansion is fueled by an escalating demand for minimally invasive anti-aging treatments, surging disposable incomes, & the heavy impact of social media on beauty standards and bioregenerative injectables, such as biostimulators and PRP. The body's natural collagen production is stimulated, offering subtle rejuvenation without surgical risks or lengthy recovery times.
About HealthNet MEA
It is a prominent UAE-based commercialization partner and distributor that manages regulatory market entry, licensing, & supply chains for international pharmaceutical and medical technology companies in the Middle East & Africa (MEA). They specialize in bringing innovative medical devices and aesthetic solutions to the rapidly growing regional cosmetic market.
The main focus is on regenerative aesthetics and dermatology. It includes Skin Revive, Hair Revive, and Anti-Aging Face Masks, bringing quantified NTA-based characterization and high exosome concentrations to the region.
About Botanical EX
Botanical EX is designed specifically for professional clinical use in the rapidly growing bioregenerative aesthetics sector. It distinguishes itself from generic exosome products through rigid manufacturing and standardized quality controls.
It is commercialized in the Middle East & Africa (MEA) through a regional distribution agreement with HealthNet MEA. It distinguishes itself from generic exosome products through rigid manufacturing and standardized quality controls.
A recent report by Towards Healthcare highlights that the Middle East & Africa bioregenerative aesthetic injectables market is witnessing growth due to the shift to non-surgical procedures, where consumers are increasingly moving away from invasive surgeries in favor of minimally invasive, natural-looking bioregenerative injectables, and a cultural shift driven by influencers heavily impacts consumer choices, promoting an emphasis on preventive aesthetics and subtle enhancements.